Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018

Abstract Background Fungal infections are responsible for >1.5 million deaths globally per year, primarily in those with compromised immune function. This is concerning as the number of immunocompromised patients, especially in those without human immunodeficiency virus (HIV), has risen in the pa...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Open forum infectious diseases Ročník 9; číslo 1; s. ofab593
Hlavní autoři: Rayens, Emily, Norris, Karen A
Médium: Journal Article
Jazyk:angličtina
Vydáno: US Oxford University Press 01.01.2022
Témata:
Ambulatory care
Fungal infections
Health care expenditures
Major
Mortality
United States > US
mycoses
National Inpatient Sample
HCUP
mortality
NIS
Healthcare Cost and Utilization Project
fungal disease
ISSN:2328-8957, 2328-8957
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Abstract Background Fungal infections are responsible for >1.5 million deaths globally per year, primarily in those with compromised immune function. This is concerning as the number of immunocompromised patients, especially in those without human immunodeficiency virus (HIV), has risen in the past decade. The purpose of this analysis was to provide the current prevalence and impact of fungal disease in the United States. Methods We analyzed hospital discharge data from the most recent (2018) Healthcare Cost and Utilization Project National Inpatient Sample, and outpatient visit data from the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey. Costs are presented in 2018 United States (US) dollars. Results In the 35.5 million inpatient visits documented in 2018 in the US, approximately 666 235 fungal infections were diagnosed, with an estimated attributable cost of $6.7 billion. Aspergillus, Pneumocystis, and Candida infections accounted for 76.3% of fungal infections diagnosed, and 81.1% of associated costs. Most fungal disease occurred in patients with elevated risk of infection. The visit costs, lengths of stay, and risks of mortality in this population were more than twice that of those without fungal diagnoses. A further 6.6 million fungal infections were diagnosed during outpatient visits. Conclusions Fungal disease is a serious clinical concern with substantial healthcare costs and significant increases in morbidity and mortality, particularly among predisposed patients. Increased surveillance, standardized treatment guidelines, and improvement in diagnostics and therapeutics are needed to support the rising numbers of at-risk patients. Fungal infections significantly increase the morbidity, mortality, and treatment costs in hospitalized patients. As the healthcare burden of fungal infections continues to grow, substantial improvement is needed in surveillance, standardized treatment guidelines, and diagnostics and therapeutics.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2328-8957
2328-8957
DOI:10.1093/ofid/ofab593